|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bone marrow derived stem cells for the treatment of end-stage liver disease显示文摘End-stage disease due to liver cirrhosis is an important cause of death worldwide. Cirrhosis results from progressive, extensive fibrosis and impaired hepatocyte regeneration. The only curative treatment is liver transplantation, but due to the several limitations of this procedure, the interest in alternative therapeutic strategies is increasing. In particular, the potential of bone marrow stem cell(BMSC) therapy in cirrhosis has been explored in different trials. In this article, we evaluate the results of 18 prospective clinical trials, and we provide a descriptive overview of recent advances in the research on hepatic regenerative medicine. The main message from the currently available data in the literature is that BMSC therapy is extremely promising in the context of liver cirrhosis. However, its application should be further explored in randomized, controlled trials with large cohorts and long follow-ups. | Cristina Margini Ranka Vukotic Lucia Brodosi Mauro Bernardi Pietro Andreone | 2014 | World Journal of Gastroenterology2014，20，27： | 18 |
| 2 | More anxious than depressed:prevalence and correlates in a 15-nation study of anxiety disorders in people with type 2 diabetes mellitus显示文摘Background Anxiety disorder, one of the highly disabling, prevalent and common mental disorders, is known to be more prevalent in persons with type 2 diabetes mellitus (T2DM) than the general population, and the comorbid presence of anxiety disorders is known to have an impact on the diabetes outcome and the quality of life. However, the information on the type of anxiety disorder and its prevalence in persons with T2DM is limited. Aims To assess the prevalence and correlates of anxiety disorder in people with type 2 diabetes in different countries. Methods People aged 18-65 years with diabetes and treated in outpatient settings were recruited in 15 countries and underwent a psychiatric interview with the Mini-International Neuropsychiatric Interview. Demographic and medical record data were collected. Results A total of 3170 people with type 2 diabetes (56.2% women;with mean (SD) duration of diabetes 10.01 (7.0) years) participated. The overall prevalence of anxiety disorders in type 2 diabetic persons was 18%;however, 2.8% of the study population had more than one type of anxiety disorder. The most prevalent anxiety disorders were generalised anxiety disorder (8.1%) and panic disorder (5.1%). Female gender, presence of diabetic complications, longer duration of diabetes and poorer glycaemic control (HbA1c levels) were significantly associated with comorbid anxiety disorder. A higher prevalence of anxiety disorders was observed in Ukraine, Saudi Arabia and Argentina with a lower prevalence in Bangladesh and India. Conclusions Our international study shows that people with type 2 diabetes have a high prevalence of anxiety disorders, especially women, those with diabetic complications, those with a longer duration of diabetes and poorer glycaemic control. Early identification and appropriate timely care of psychiatric problems of people with type 2 diabetes is warranted. | Santosh K Chaturvedi Shayanth Manche Gowda Helal Uddin Ahmed Fahad D Alosaimi Nicola Andreone Alexey Bobrov Viola Bulgari Giuseppe Carra Gianluca Castelnuovo Giovanni de Girolamo Tomasz Gondek Nikola Jovanovic Thummala Kamala Andrzej Ki Nebojsa Lalic Dusica Lecic-Tosevski Fareed Minhas Victoria Mutiso David Ndetei Golam Rabbani Suntibenchakul Somruk Sathyanarayana Srikanta Rizwan Taj Umberto Valentini Olivera Vukovic Wolfgang Wolwer Larry Cimino Arie Nouwen Cathy Lloyd Norman Sartorius | 2019 | General Psychiatry2019，32，4： | 11 |
| 3 | Stem cells for end stage liver disease: How far have we got?显示文摘End stage liver disease (ESLD) is a health problem worldwide. Liver transplantation is currently the only effective therapy, but its many drawbacks include a shortage of donors, operative damage, risk of rejection and in some cases recidivism of the pre-transplant disease. These factors account for the recent growing interest in regenerative medicine. Experiments have sought to identify an optimal source of stem cells, sufficient to generate large amounts of hepatocytes to be used in bioartificial livers or injected in vivo to repair the diseased organ. This update aims to give non-stem cell specialists an overview of the results obtained to date in this fascinating field of biomedical research. | Stefania Lorenzini Stefano Gitto Elena Grandini Pietro Andreone Mauro Bernardi | 2008 | World Journal of Gastroenterology2008，14，29： | 8 |
| 4 | Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature显示文摘The scarcity of available organs and the gap between supply and demand continue to be the main limitations of liver transplantation. To relieve the organ shortage, current transplant strategies have implemented extended criteria, which include the use of liver from patients with signs of past or present hepatitis B virus(HBV) infection. While the use of liver grafts from donors with evidence of past HBV infection is quite limited, some data have been collected regarding the feasibility of transplanting a liver graft from a hepatitis B surface antigen(HBs Ag) positive donor. The aim of the present work was to review the literature regarding liver transplants from HBs Ag-positive donors. A total of 17 studies were identified by a search in Medline. To date, HBs Ag positive grafts have preferentially been allocated to HBs Ag positive recipients. The large majority of these patients continue to be HBs Ag positive despite the use of immunoglobulin, and infection prevention can only be guaranteed by using antiviral prophylaxis. Although serological persistence is evident, no significant HBV-related disease has been observed, except in patients coinfected with delta virus. Consistently less data are available for HBs Ag negative recipients, although they are mostly promising. HBs Agpositive grafts could be an additional organ source for liver transplantation, provided that the risk of reinfection/reactivation is properly prevented. | Elisabetta Loggi Fabio Conti Alessandro Cucchetti Giorgio Ercolani Antonio Daniele Pinna Pietro Andreone | 2016 | World Journal of Gastroenterology2016，22，35： | 5 |
| 5 | De novo autoimmune hepatitis in liver transplant: State-of-the-art review显示文摘In the two past decades, a number of communications, case-control studies, and retrospective reports have appeared in the literature with concerns about the development of a complex set of clinical, laboratory and histological characteristics of a liver graft dysfunction that is compatible with autoimmune hepatitis. The de novo prefix was added to distinguish this entity from a pre-transplant primary autoimmune hepatitis, but the globally accepted criteria for the diagnosis of autoimmune hepatitis have been adopted in the diagnostic algorithm. Indeed, de novo autoimmune hepatitis is characterized by the typical liver necroinflammation that is rich in plasma cells, the presence of interface hepatitis and the consequent laboratory findings of elevations in liver enzymes, increases in serum gamma globulin and the appearance of nonorgan specific auto-antibodies. Still, the overall features of de novo autoimmune hepatitis appear not to be attributable to a univocal patho-physiological pathway because they can develop in the patients who have undergone liver transplantation due to different etiologies. Specifically, in subjects with hepatitis C virus recurrence, an interferon-containing antiviral treatment has been indicated as a potential inception of immune system derangement. Herein, we attempt to review the currently available knowledge about de novo liver autoimmunity and its clinical management. | Ranka Vukotic Giovanni Vitale Antonia D'Errico-Grigioni Luigi Muratori Pietro Andreone | 2016 | World Journal of Gastroenterology2016，22，10： | 4 |
| 6 | Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach显示文摘 | Calogero Cammà Marco Giunta Pietro Andreone Antonio Crax?? | 2001 | Journal of Hepatology2001，，4： | 2 |
| 7 | Liver transplantation from hepatitis B surface antigen positive donors: A safe way to expand the donor pool显示文摘 | Elisabetta Loggi Lorenzo Micco Giorgio Ercolani Alessandro Cucchetti Florian K. Bihl Gian Luca Grazi Stefano Gitto Andrea Bontadini Mauro Bernardi Paolo Grossi Alessandro Nanni Costa Antonio Daniele Pinna Christian Brander Pietro Andreone | 2011 | Journal of Hepatology2011，，3： | 2 |
| 8 | The amino acid sequence of rat liver glucokinase deduced from cloned cDNA显示文摘 | Andreone T L Andreone T L Pilkis S J | 1989 | Biol Chem1989，264，1： | 2 |
| 9 | Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis:a systematic review and meta-analysis显示文摘AIM To assess vitamin E efficacy,defined as its ability to induce hepatitis B e antigen(HBeAg) seroconversion,in children with HBeAg-positive persistent hepatitis.METHODS In July 2016,we extracted articles published in MEDLINE and the Cochrane Library using the following search terms:'chronic hepatitis B','children','childhood','therapy','treatment','vitamin E','tocopherols','tocotrienols'.Only randomized controlled trials(RCTs) published in English language were collected.RESULTS Three RCTs met inclusion criteria and were considered in the present meta-analysis.Overall,23/122 children in the treatment group underwent HBeAg seroconversion vs 3/74 in the control group(OR=3.96,95%CI:1.18-13.25,P=0.025).CONCLUSION Although our meta-analysis has several limits,including the very small number of available studies and enrolled children with HBeAg positivity-related hepatitis,it suggests that vitamin E use may enhance the probability to induce HBeAg seroconversion in these patients.Further well designed and adequately sized trials are required to confirm or deny these very preliminary results. | Sirio Fiorino Maria Letizia Bacchi-Reggiani Paolo Leandri Elisabetta Loggi Pietro Andreone | 2017 | World Journal of Hepatology2017，9，6： | 2 |
| 10 | Hepatitis C virus recurrence after liver transplantation:A 10-year evaluation显示文摘AIM: To evaluate the predictors of 10-year survival of patients with hepatitis C recurrence. METHODS: Data from 358 patients transplanted between 1989 and 2010 in two Italian transplant centers and with evidence of hepatitis C recurrence were analyzed. A χ2, Fisher's exact test and Kruskal Wallis' test were used for categorical and continuous variables, respectively. Survival analysis was performed at 10 years after transplant using the Kaplan-Meier method, and a log-rank test was used to compare groups. A P level less than 0.05 was considered significant for all tests. Multivariate analysis of the predictive role of different variables on 10-year survival was performed by a stepwise Cox logistic regression.RESULTS: The ten-year survival of the entire population was 61.2%. Five groups of patients were identified according to the virological response or lack of a response to antiviral treatment and, among those who were not treated, according to the clinical status(mild hepatitis C recurrence, 'too sick to be treated' and patients with comorbidities contraindicating the treatment). While the 10-year survival of treated and untreated patients was not different(59.1% vs 64.7%, P = 0.192), patients with a sustained virological response had a higher 10-year survival rate than both the 'non-responders'(84.7% vs 39.8%, P < 0.0001) and too sick to be treated(84.7% vs 0%, P < 0.0001). Sustained virological responders had a survival rate comparable to patients untreated with mild recurrence(84.7% vs 89.3%). A sustained virological response and young donor age were independent predictors of 10-year survival. CONCLUSION: Sustained virological response significantly increased long-term survival. Awaiting the interferon-free regimen global availability, antiviral treatment might be questionable in selected subjects with mild hepatitis C recurrence. | Stefano Gitto Luca Saverio Belli Ranka Vukotic Stefania Lorenzini Aldo Airoldi Arrigo Francesco Giuseppe Cicero Marcello Vangeli Lucia Brodosi Arianna Martello Panno Roberto Di Donato Matteo Cescon Gian Luca Grazi Luciano De Carlis Antonio Daniele Pinna Mauro Bernardi Pietro Andreone | 2015 | World Journal of Gastroenterology2015，21，13： | 2 |
| 11 | Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial显示文摘 | M Degiuli M Sasako M Calgaro M Garino F Rebecchi M Mineccia D Scaglione D Andreone A Ponti F Calvo | 2004 | European Journal of Surgical Oncology2004，，3： | 2 |
| 12 | ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV Genotype 1b Infection显示文摘 | Pietro Andreone Massimo G. Colombo Jeffrey V. Enejosa Iftihar Koksal Peter Ferenci Andreas Maieron Beat Müllhaupt Yves Horsmans Ola Weiland Henk W. Reesink Lino Rodrigues Yiran B. Hu Thomas Podsadecki Barry Bernstein | 2014 | Gastroenterology2014，，： | 2 |
| 13 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 2 |
| 14 | Adaptive response in hepatitis B virus infection显示文摘 | E. Loggi N. Gamal F. Bihl M. Bernardi P. Andreone | 2014 | J Viral Hepat2014，，5： | 1 |
| 15 | Prophylaxis and treatment of hepatitis B in immunocompromised patients 显示文摘 | MARZANO A ANGELUCCI E ANDREONE P | 2007 | Dig liv Dis2007，39，5： | 1 |
| 16 | In vitro effect of thymosin-alphal and interferon-alpha on Thl and Th2 cytokine syn thesis in patients with chronic hepatitis C显示文摘 | Andreone P Cursaro C Gramenzi A | 2001 | J Viral Hepatitis2001，8，3： | 1 |
| 17 | Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation显示文摘 | Scott K. Fung Pietro Andreone Steve H. Han K. Rajender Reddy Arie Regev Emmet B. Keeffe Munira Hussain Carmela Cursaro Pamela Richtmyer Jorge A. Marrero Anna S.F. Lok | 2005 | Journal of Hepatology2005，，6： | 1 |
| 18 | A randomized controlled trial of thymosin-alphal versus interferon alpha treatment in patients with hepatitis B antigen antibody and hepatitis B virus DNA-positive chronic hepatitis B 显示文摘 | Andreone P Cursaro C Gramenzi A | 1996 | Hepatology1996，24，4： | 1 |
| 19 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 1 |
| 20 | Adefovir resistant hepatitis B can be associated with viral rebound and hepatic decompensation显示文摘 | Fung SK Andreone P Han SH | 2005 | J Hepatol2005，43，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员